Alam Shirjel R, Shah Anoop S V, Ombati Kevin O, Nganga Edward, Gitau Samuel, Makhdomi Khalid, Chung Michael H, Vinayak Sudhir
Manchester University, Manchester, UK.
London School of Hygiene and Tropical Medicine, London, UK.
BMC Cardiovasc Disord. 2021 May 8;21(1):234. doi: 10.1186/s12872-021-02027-0.
8-28% of patients infected with COVID-19 have evidence of cardiac injury, and this is associated with an adverse prognosis. The cardiovascular mechanisms of injury are poorly understood and speculative. We aim to use multimodality cardiac imaging including cardiac magnetic resonance (CMR) imaging, computed tomography coronary angiography (CTCA) and positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG-PET/CT) to identify the cardiac pathophysiological mechanisms related to COVID-19 infections.
This is a single-centre exploratory observational study aiming to recruit 50 patients with COVID-19 infection who will undergo cardiac biomarker sampling. Of these, 30 patients will undergo combined CTCA and 18F-FDG-PET/CT, followed by CMR. Prevalence of obstructive and non-obstructive atherosclerotic coronary disease will be assessed using CTCA. CMR will be used to identify and characterise myocardial disease including presence of cardiac dysfunction, myocardial fibrosis, myocardial oedema and myocardial infarction. 18F-FDG-PET/CT will identify vascular and cardiac inflammation. Primary endpoint will be the presence of cardiovascular pathology and the association with troponin levels.
The results of the study will identify the presence and modality of cardiac injury associated COVID-19 infection, and the utility of multi-modality imaging in diagnosing such injury. This will further inform clinical decision making during the pandemic.
This study has been retrospectively registered at the ISRCTN registry (ID ISRCTN12154994) on 14th August 2020. Accessible at https://www.isrctn.com/ISRCTN12154994.
感染新型冠状病毒肺炎(COVID-19)的患者中有8%-28%存在心脏损伤证据,且这与不良预后相关。损伤的心血管机制尚不清楚,目前只是推测。我们旨在使用多模态心脏成像,包括心脏磁共振(CMR)成像、计算机断层扫描冠状动脉造影(CTCA)以及结合计算机断层扫描的2-脱氧-2-[氟-18]氟-D-葡萄糖正电子发射断层扫描(18F-FDG-PET/CT),以确定与COVID-19感染相关的心脏病理生理机制。
这是一项单中心探索性观察性研究,旨在招募50例COVID-19感染患者并进行心脏生物标志物采样。其中,30例患者将接受CTCA和18F-FDG-PET/CT联合检查,随后进行CMR检查。使用CTCA评估阻塞性和非阻塞性动脉粥样硬化性冠状动脉疾病的患病率。CMR将用于识别和表征心肌病,包括心脏功能障碍、心肌纤维化、心肌水肿和心肌梗死的存在情况。18F-FDG-PET/CT将识别血管和心脏炎症。主要终点将是心血管病理学的存在情况及其与肌钙蛋白水平的关联。
该研究结果将确定与COVID-19感染相关的心脏损伤的存在情况和模式,以及多模态成像在诊断此类损伤中的效用。这将为疫情期间的临床决策提供更多信息。
本研究已于2020年8月14日在国际标准随机对照试验编号注册库(ID:ISRCTN12154994)进行回顾性注册。可在https://www.isrctn.com/ISRCTN12154994查询。